In just a few years, drugs such as Ozempic, Wegovy, and Mounjaro have evolved from discreet diabetes treatments to major social phenomena. Their promise of weight loss through simple weekly injections has opened a new chapter not only in human medicine but potentially for our feline friends as well. Cats may soon receive adapted versions of these treatments, addressing a rising issue: feline obesity.
Goodbye Fat Cats
Okava Pharmaceuticals, a San Francisco-based company specializing in chronic diseases affecting companion animals, has initiated a groundbreaking clinical trial called MEOW-1. This study aims to evaluate the safety and effectiveness of OKV-119, a subdermal implant that releases exenatide, a GLP-1 agonist, for months in overweight or obese cats.
Simplifying Treatment for Cats
The intervention seeks to streamline what in human medicine usually involves weekly injections. In this case, treatment boils down to one simple procedure. “You insert the capsule under the skin, and six months later, you come back, and the cat has lost weight. It’s like magic,” explains Chen Gilor, the veterinarian leading the study, in an interview with The New York Times.
A Pioneering Study
Okava’s venture into feline obesity treatments stems from extensive preliminary research. Prior to MEOW-1, the company evaluated prototype implants in two studies. One published in Frontiers in Veterinary Science confirmed that the OKV-119 implant was easy to implant and remove, well tolerated, and effective in reducing weight in healthy cats over a month.
Subsequent research reported in BMC Veterinary Research observed stable exenatide levels in five implanted cats over 84 days, with four of them losing a minimum of 5% of their body weight. These promising results paved the way for trials involving real obese cats this summer. According to the company, MEOW-1 represents the first formal study focusing on feline weight loss using GLP-1 agonists.
How Does the Implant Work?
OKV-119 utilizes the NanoPortal platform created by Vivani Medical. Studies indicate that this technology incorporates a titanium reservoir and a regulated membrane that ensures constant and prolonged drug release without significant fluctuations.
This method effectively addresses a major hurdle in veterinary medicine: low adherence to treatment. Studies show that administering repeated injections can be stressful for cats and caregivers alike, reducing treatment consistency. The OKV-119 implant offers a one-and-done solution: a subdermal insertion in a veterinary setting, requiring no ongoing caregiver intervention.
Veterinarians are reported to be using human GLP-1 agonists off-label in diabetic cats, but frequent administration and high costs limit this practice. Thus, the relevance of an implant that could keep medication active for up to six months is immense.
But Is This Just for Cats?
While MEOW-1 primarily targets felines, Okava and Vivani have announced plans to expand the project to dogs, who are also facing high obesity rates in the U.S. This expansion aims to replicate the positive metabolic effects seen in cats, improving insulin sensitivity, reducing fat mass, and increasing energy efficiency.
The Feline Obesity Epidemic
The interest in an “Ozempic for cats” is not merely a trend but a direct response to a serious issue. A review published in Journal of Feline Medicine and Surgery found that feline overweight prevalence ranges from 40% to 63%, a figure that’s steadily increasing. Common contributing factors include indoor living, minimal exercise, constant food availability, excessive treats, sterilization, and a lack of owner awareness regarding their cat’s weight gain.
Consequences of Feline Obesity
The ramifications of this epidemic are severe, including insulin resistance, diabetes, joint issues, urinary problems, anesthetic complications, and liver disorders, ultimately leading to reduced life expectancy. Recent proteomic analyses highlight widespread changes in inflammatory processes and lipid metabolism in obese cats, indicating that feline obesity is more than a superficial concern.
Challenges Ahead
Despite the promise of MEOW-1, mass adoption of an “Ozempic for cats” is not guaranteed. The first hurdle is cost; human GLP-1 medications are expensive, and it remains uncertain whether a veterinary implant will be affordable for most caregivers. Cost could deter adoption, especially since feline obesity, while common, is not always viewed as urgent.
Second, the scientific evidence is still emerging. Initial studies with OKV-119 involved small sample sizes (5-15 cats), leaving uncertainties about larger-scale applications and the response of animals with pre-existing conditions or varied home environments.
Lastly, there’s the concern of scientific independence; most research on OKV-119 has been conducted by teams directly associated with Okava or Vivani, raising questions about the objectivity of the findings.
A New Era in Feline Medicine?
The ongoing trial raises pressing questions: Will these promising results suffice for regulatory approval? Will caregivers change their feeding practices? And what are the long-term effects of pharmacologically modifying a pet’s appetite and metabolism in a domestic setting?
Answers will emerge with the MEOW-1 results and future trials. For now, “Ozempic for cats” is no longer just a futuristic concept but an active experiment that may reshape how we approach the metabolic health of our feline companions.
Xataka | We are discovering how the brain “hacks” us to make us hungry. And it is a key step in the race towards losing weight.